Posted: Monday, July 19, 2021
Research published in the American Journal of Hematology reports on reportedly the largest cohort of patients with acute myeloid leukemia (AML) treated with venetoclax combinations outside of clinical trials. Conducted by Maya Koren-Michowitz, MD, of Tel Aviv University, and colleagues, the study focused on data from 11 Israeli medical centers and included 133 patients with AML treated with venetoclax and either hypomethylating agents or low-dose cytarabine.
“Our real-life data support and extend the results obtained from clinical trials of venetoclax combinations in AML patients not eligible for intensive therapy. Secondary AML patients could benefit from venetoclax combinations, similarly to de novo AML patients, and allo-SCT [allogeneic stem cell transplantation] could be offered to selected patients achieving [complete remission/complete remission with incomplete count recovery],” the authors commented.
The mean age of participants at the time of treatment was 77, with patients ranging from aged 52 to 95. More than half of the study patients had secondary AML.
The majority of participants (61%) achieved complete remission and complete remission with incomplete blood cell count recovery. Similar remission rates were observed in patients with secondary AML and in those previously treated with hypomethylating agents, 61% and 43%, respectively. About one-quarter of participants experienced relapse. Median overall survival in the entire cohort was 9.8 months (95% confidence interval = 6.42–13.3 months), though higher median overall survival was observed in patients achieving complete remission and complete remission with incomplete blood cell count recovery and in those proceeding to allogeneic stem cell transplantation.
According to the investigators, these results support the efficacy and safety of venetoclax combinations in patients with AML treated outside of clinical trials.
Disclosure: The authors reported no conflicts of interest.